Acrux Limited

ASX:ACR ISIN:AU000000ACR3

 Acrux is a specialty pharmaceutical company, developing and commercialising a range of patented, patient-preferred healthcare products for global markets, using its innovative technology to administer drugs through the skin. Acrux's product pipeline includes treatments of hormonal deficiencies, pain, central nervous system disorders and a contraceptive. Acrux has also licensed its technology to Eli Lilly for veterinary healthcare products.  
 
     

查看其它語言版本

新聞

6月22日澳洲股市:打破跌勢

🕔6/22/2009 1:00:22 PM 19147

上週五,澳洲股市在一周之中首次收漲。基本指數S&P/ASX200上漲7.5點,或0.19%,報3,899.6點,綜合指數上漲7點,或0.18%,報3894.4點。

閱讀全文
###

49,963 公司背景瀏覽

  • 本頁瀏覽人次: (過去7日: 29) (過去30日: 120) (自發布以來: 8468) 

公司詳細

    傳真
  • (03) 8379 0101 
  • 主要部門
  • 醫療-製藥 
  • 支柱產業
  • 生物科技 
  • 主頁
  • www.acrux.com.au

更多新聞紀錄

  • 2025/04/04: Appendix 3Y Dobinson*
  • 2025/04/04: Application for quotation of securities - ACR*
  • 2025/04/03: Acrux receives $1.73m advance on FY25 R&D Tax Incentive*
  • 2025/03/07: Attaching Options final application date 31 March 2025*
  • 2025/03/06: Notification of cessation of securities - ACR*
  • 2025/03/04: Appendix 3Y Dobinson*
  • 2025/03/03: Cleansing Notice*
  • 2025/03/03: Application for quotation of securities - ACR*
  • 2025/02/25: Investor Presentation February 2025*
  • 2025/02/25: Investor Webinar Announcement*
*refer to company website